Search | Clinical Trials Finder

Conditions: Autism Spectrum Disorders, Normal Hearing, Normal Intelligence, Exhibit Self- Stimulating or Ritualistic Behaviors
Interventions: ProFoveate; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 10 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: HSV-2
Interventions: AIC316, Placebo; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Miami, Florida • Indianapolis, Indiana • Portland, Oregon + 3 more

Conditions: Osteoarthritis, Knee
Interventions: Lumiracoxib; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,464 participants
Timeline: Started 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 18 more

Conditions: Infertility (IVF Patients), Infertility, Infertility Female
Interventions: CAPA-IVM, In-House CAPA-IVM Pre-Maturation Medium, Minimal-Stimulation OS-IVF; Procedure · Device
Lead sponsor: New Hope Fertility Center; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Risankizumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 44
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more

Conditions: Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
Interventions: Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Pelvic Pain, Headaches, Emotional
Interventions: loestrin 24/4 vs loestrin 1/20, loestrin 1/20; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Pain Management, Opioid Use, Prostate Cancer
Interventions: Oxycodone, Acetaminophen, Ketamine, Ketorolac; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypertension, Medication Adherence
Interventions: Text Message, Behavior Economic Incentive; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes
Interventions: CRx Health, Chronicare; Other
Lead sponsor: QuiO; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Midland, Michigan

Conditions: Hepatitis C
Interventions: Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 22
States / cities: Dothan, Alabama • Hoover, Alabama • Phoenix, Arizona + 19 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 72 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions: Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 10
States / cities: Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 54
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more

Conditions: Hidradenitis Suppurativa
Interventions: SAR445399, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Scottsdale, Arizona • North Hollywood, California • Boynton Beach, Florida + 16 more

Conditions: Alcohol Dependence, Bipolar Disorder, Depression, Mania, Psychosis
Interventions: Lamotrigine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Colon Cancer Screening
Interventions: Chewing Sugar-Free Gum During Bowel Preparation, Standard Bowel Prep (2L PEG-ELP), Standard Bowel Prep; Behavioral · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 45 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions: LV305, G305, LV305-matching placebo, G305-matching placebo; Biological · Other
Lead sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more

Conditions: Hyperinsulinism, Diabetes, Pancreatic Diseases, Pancreatectomy; Hyperglycemia
Interventions: Bihormonal Bionic Pancreas; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Fasinumab, Diclofenac, Celecoxib, Matching placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 71
States / cities: Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more

Search by objective public record fields.

The Effects of ProFoveate on Reducing Self-Stimulating Behaviors

Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

Intra-ovarian CAPA-IVM vs Standard IVM

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Behavioral Economics to Improve Antihypertensive Therapy Adherence

Chronicare for Type 2 Diabetes (Chronicare-T2D)

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Treatment of Alcohol Dependence and Comorbid Bipolar Disorder

Impact of Chewing Gum on Bowel Preparation in Patients Undergoing Colonoscopy

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip